GO:0042164 interleukin-12 alpha subunit binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042164 (interleukin-12 alpha subunit binding) is a molecular_function term defined as binding to the alpha subunit of interleukin-12 (IL-12A/p35).
• IL-12 is a heterodimeric cytokine composed of an alpha subunit (p35/IL-12A) and a beta subunit (p40/IL-12B); the alpha subunit is shared with IL-23 and IL-39.
• Proteins that bind IL-12A include the IL-12 receptor beta-2 (IL12RB2) and other partners that regulate cytokine assembly, secretion, and signaling.
• Dysregulated IL-12/IL-23 signaling is implicated in psoriasis, inflammatory bowel disease, and other immune-mediated disorders, making this binding event a therapeutic target.
• Therapeutic antibodies such as risankizumab and ustekinumab target IL-12/23 subunits and have shown efficacy in psoriasis and ulcerative colitis, underscoring the clinical relevance of IL-12A binding.
• Research on GO:0042164 benefits from CRISPR knockout, knock-in, and overexpression models to dissect the functional consequences of IL-12A interactions.
Description
Interleukin-12 (IL-12) is a heterodimeric cytokine that plays a central role in bridging innate and adaptive immunity. It is composed of an alpha subunit (p35, encoded by IL12A) and a beta subunit (p40, encoded by IL12B). The molecular function GO:0042164, interleukin-12 alpha subunit binding, describes the selective interaction of proteins with the IL-12 alpha subunit. This binding event is critical for cytokine assembly, receptor engagement, and downstream signaling. Understanding this function is essential for researchers studying immune regulation, inflammatory diseases, and cytokine-targeted therapies. The alpha subunit of IL-12 is shared with other cytokines of the IL-12 family, including IL-23 and IL-39, which adds complexity to its functional roles. Proteins that bind IL-12A can influence cytokine secretion, stability, and receptor binding, thereby modulating immune responses. Dysregulation of IL-12 signaling has been linked to autoimmune and inflammatory conditions such as psoriasis and inflammatory bowel disease. Consequently, GO:0042164 is a focal point for both basic immunology and drug discovery. This article provides a comprehensive overview of the interleukin-12 alpha subunit binding function, integrating authoritative GO annotations with published literature. We cover the definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental models, with a focus on CRISPR-based approaches for functional studies.
interleukin-12 alpha subunit binding At A Glance
| GO ID | GO:0042164 |
|---|---|
| GO term | interleukin-12 alpha subunit binding |
| Ontology | molecular_function |
| Synonym | CLMFp35 binding, IL-12A binding, IL-12p35 binding, NKSFp35 binding |
| Major function | Binding to the alpha subunit (p35/IL-12A) of interleukin-12 |
| Cytokine family | IL-12 family (IL-12, IL-23, IL-39 share the alpha subunit) |
| Related genes | IL12A, IL12B, IL12RB1, IL12RB2, and other interacting partners |
| Therapeutic relevance | Targeted by antibodies such as risankizumab and ustekinumab |
What Is GO:0042164?
According to the Gene Ontology, GO:0042164 (interleukin-12 alpha subunit binding) is defined as the binding to the alpha subunit of interleukin-12. In other words, it is a molecular function that enables a protein to selectively interact with the p35 (IL-12A) subunit of the IL-12 cytokine. This binding can occur during cytokine assembly, receptor complex formation, or regulatory interactions. The term is synonymous with CLMFp35 binding, IL-12A binding, IL-12p35 binding, and NKSFp35 binding, reflecting historical names for the same subunit.
Why Is interleukin-12 alpha subunit binding Important in Cell Biology?
The binding of proteins to the interleukin-12 alpha subunit is a fundamental event in cytokine biology and immune regulation. IL-12 is a key driver of T-helper 1 (Th1) responses, and its alpha subunit is shared with IL-23 and IL-39, which are involved in Th17 responses and inflammation. Therefore, molecular interactions with IL-12A can modulate multiple cytokine pathways. This function is important for understanding how immune cells communicate and how dysregulation leads to autoimmune and inflammatory diseases. Moreover, therapeutic strategies that block IL-12/23 signaling, such as monoclonal antibodies, rely on disrupting these binding events, making GO:0042164 a clinically relevant target.
• IL-12 alpha subunit binding is essential for the assembly and secretion of the heterodimeric IL-12 cytokine.
• The alpha subunit (p35) is shared with IL-23 and IL-39, so binding events can influence multiple inflammatory pathways.
• IL-12 signaling promotes Th1 differentiation and interferon-gamma production, which are critical for host defense.
• Dysregulated IL-12/23 signaling is implicated in psoriasis, inflammatory bowel disease, and other immune-mediated disorders.
• Therapeutic antibodies targeting IL-12/23 subunits (e.g., risankizumab, ustekinumab) have demonstrated clinical efficacy, validating the importance of these binding interactions.
• Studying IL-12A binding helps elucidate mechanisms of cytokine receptor activation and signal transduction.
• Genetic and epigenetic factors regulating innate immune responses can affect IL-12 family cytokine expression.
• IL-12 family cytokines are also being explored in the context of gout and other inflammatory conditions.
• Understanding IL-12A binding can inform the design of small-molecule inhibitors or biologics for autoimmune diseases.
• CRISPR-based models enable precise dissection of the functional domains involved in IL-12A binding.
Molecular Mechanism of interleukin-12 alpha subunit binding
Cytokine Assembly and Heterodimerization
In simple terms: The alpha subunit of IL-12 must pair with the beta subunit to form the active cytokine.
IL-12 is a heterodimeric cytokine composed of an alpha subunit (p35, IL-12A) and a beta subunit (p40, IL-12B). The binding of proteins to the alpha subunit can influence the assembly and stability of this heterodimer. For example, the p35 subunit requires association with p40 for efficient secretion and function. This assembly process is critical for generating biologically active IL-12 that can engage its receptor.
Receptor Recognition and Binding
In simple terms: Once formed, IL-12 binds to its receptor, and the alpha subunit plays a key role in this interaction.
The IL-12 receptor is composed of IL12RB1 and IL12RB2 subunits. The alpha subunit (p35) contributes to receptor binding and signaling. Proteins that bind IL-12A may compete with or modulate receptor engagement, thereby affecting downstream signaling pathways such as JAK-STAT activation. This binding specificity ensures that IL-12 signals through the appropriate receptor complex.
Shared Subunit Complexity
In simple terms: The alpha subunit is shared with other cytokines, so binding can affect multiple pathways.
IL-12A (p35) is also a component of IL-23 (paired with p19) and IL-39 (paired with EBI3). Therefore, proteins that bind to IL-12A can potentially influence the assembly or activity of these related cytokines. This shared usage adds a layer of complexity to the regulation of immune responses and means that targeting IL-12A binding could have broad effects on Th1 and Th17 pathways.
Regulation by Soluble and Membrane-Bound Partners
In simple terms: Various proteins can bind to IL-12A and regulate its availability or function.
Beyond the receptor, other proteins may bind to IL-12A to regulate its secretion, stability, or activity. For instance, the IL-12 family cytokines are subject to regulation by soluble receptors, decoy molecules, or intracellular chaperones. The exact partners that bind IL-12A are an area of active research, and understanding these interactions can reveal new therapeutic targets.
Key Genes Involved in GO:0042164 interleukin-12 alpha subunit binding
The following genes encode proteins that are directly or indirectly involved in interleukin-12 alpha subunit binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL12A | Encodes the alpha subunit (p35) of IL-12 | Core component of the binding event; target for knockout and mutagenesis |
| IL12B | Encodes the beta subunit (p40) of IL-12 | Forms heterodimer with IL-12A; affects binding and secretion |
| IL12RB1 | IL-12 receptor beta-1 subunit | Mediates receptor binding and signaling; interacts with IL-12 |
| IL12RB2 | IL-12 receptor beta-2 subunit | Confers high-affinity binding and signaling specificity |
| IL23A | Encodes p19 subunit of IL-23 | Shares IL-12A as partner; relevant to Th17 biology |
| EBI3 | Encodes Epstein-Barr virus induced 3 | Partners with IL-12A in IL-39; modulates immune responses |
| JAK2 | Janus kinase 2 | Downstream signaling kinase activated by IL-12 receptor |
| TYK2 | Tyrosine kinase 2 | Associates with IL-12 receptor and mediates STAT activation |
| STAT4 | Signal transducer and activator of transcription 4 | Key transcription factor downstream of IL-12 signaling |
| IFNG | Interferon gamma | Major effector cytokine induced by IL-12; readout of pathway activity |
| TNFSF15 | TL1A cytokine | Regulates Th1 and Th17 responses; may intersect with IL-12 family |
| IL18 | Interleukin-18 | Proinflammatory cytokine that synergizes with IL-12 |
| NLRP3 | NLR family pyrin domain containing 3 | Inflammasome component linked to IL-1 family and innate immunity |
| IL39 | Interleukin-39 (IL-12A/EBI3 heterodimer) | New member of IL-12 family; shares alpha subunit |
| IL12RB2 | IL-12 receptor beta-2 | Polymorphisms associated with autoimmune diseases |
| IL12A | Interleukin 12 alpha | Genetic variants linked to Sjögren's syndrome and other autoimmune conditions |
| IL23R | Interleukin 23 receptor | Shares signaling components with IL-12; target in IBD |
| JAK1 | Janus kinase 1 | Participates in cytokine receptor signaling including IL-12 family |
How Is interleukin-12 alpha subunit binding Regulated?
The binding of proteins to the interleukin-12 alpha subunit is regulated at multiple levels. Transcriptional regulation of IL12A and IL12B genes controls the availability of subunits for assembly. Post-translational modifications, such as glycosylation, can affect subunit stability and secretion. Additionally, soluble receptors and decoy molecules can compete for binding to IL-12A, modulating its bioavailability. Cytokines such as interferon-gamma and interleukin-18 can influence IL-12 production and function, creating feedback loops. In the context of disease, epigenetic modifications may alter the expression of IL-12 family genes, as observed in innate immune responses to gout. Understanding these regulatory mechanisms is crucial for targeting IL-12A binding in therapeutic settings.
interleukin-12 alpha subunit binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL12A | Psoriasis, IBD, autoimmune conditions | Knockout mice or cell lines to study cytokine assembly and signaling |
| IL12B | Psoriasis, IBD | Knock-in of risk variants to assess binding and secretion |
| IL12RB2 | Sjögren's syndrome, autoimmunity | CRISPR knockout in immune cells to test receptor function |
| IL23A | Psoriasis, IBD | Overexpression models to study IL-23/IL-12A interactions |
| EBI3 | Inflammatory diseases | Knockout models to dissect IL-39 function |
Psoriasis and Inflammatory Skin Diseases
Psoriasis is a chronic inflammatory skin disease driven by dysregulated IL-12/IL-23 signaling. The alpha subunit of IL-12 is a component of both cytokines, and therapeutic antibodies such as risankizumab, which targets the p19 subunit of IL-23, and ustekinumab, which targets p40, have shown significant efficacy in plaque psoriasis. These therapies indirectly affect IL-12A binding by neutralizing the shared subunits. Therefore, understanding the molecular interactions of IL-12A is essential for developing new treatments for psoriasis and related conditions.
Inflammatory Bowel Disease (IBD)
Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are associated with aberrant IL-12/IL-23 signaling. Ustekinumab, a monoclonal antibody against the p40 subunit shared by IL-12 and IL-23, has been approved for moderate-to-severe ulcerative colitis. This highlights the clinical relevance of targeting the IL-12 family, including the alpha subunit, in intestinal inflammation. Research into IL-12A binding may reveal additional therapeutic strategies for IBD.
Autoimmune Conditions and Genetic Susceptibility
Genetic variants in IL12A and IL12RB2 have been associated with autoimmune diseases such as Sjögren's syndrome. These polymorphisms may affect the binding affinity or expression of the alpha subunit, contributing to disease pathogenesis. Additionally, IL-12 family cytokines are implicated in other autoimmune conditions, and understanding their binding interactions can provide insights into disease mechanisms and potential targets.
Gout and Innate Immunity
Gout is an inflammatory arthritis caused by monosodium urate crystals, which activate the NLRP3 inflammasome and innate immune responses. Genetic and epigenetic regulation of innate immunity, including IL-12 family cytokines, may influence gout susceptibility and severity. While direct evidence for IL-12A binding in gout is limited, the broader IL-12 family is part of the inflammatory network, and further research could clarify its role.
From interleukin-12 alpha subunit binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL12A knockout abolish IL-12 signaling? | IL12A knockout cell line (e.g., HEK293 or immune cells) |
| How do point mutations in IL12A affect binding to partners? | Point-mutation knock-in via CRISPR |
| Can tagged IL-12A be used to pull down interacting proteins? | Knock-in of epitope-tagged IL12A |
| What is the effect of IL12A overexpression on immune activation? | Overexpression cell model |
| Which domains of IL-12A are required for receptor binding? | Deletion mutants and binding assays |
| How does IL-12A binding influence downstream STAT4 activation? | Knockout and rescue experiments |
How to Study the interleukin-12 alpha subunit binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interactions | Identifying novel IL-12A binding partners |
| SPR/BLI | Binding kinetics and affinity | Characterizing mutations in IL-12A |
| CRISPR screen | Genes affecting IL-12A binding/signaling | Discovery of pathway regulators |
| Reporter assay | IL-12-induced transcriptional activity | Screening for inhibitors or activators |
| Flow cytometry | Surface binding and intracellular expression | Quantifying IL-12A levels and receptor occupancy |
| Mass spectrometry | Identification of binding partners | Proteomic analysis of IL-12A complexes |
| ELISA | Cytokine secretion | Measuring IL-12 or IFN-gamma production |
| Western blot | Protein expression and phosphorylation | Assessing STAT4 activation |
Co-Immunoprecipitation (Co-IP) and Pull-Down Assays
Co-immunoprecipitation is a classic method to detect protein-protein interactions involving IL-12A. By using antibodies against IL-12A or a tagged version, researchers can isolate binding partners from cell lysates and identify them by mass spectrometry. This approach has been used to study cytokine-receptor interactions and can reveal novel proteins that bind the alpha subunit.
Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI)
These biophysical techniques measure real-time binding kinetics and affinity between IL-12A and its partners. SPR and BLI can quantify association and dissociation rates, providing insights into the strength and specificity of interactions. Such methods are valuable for characterizing mutations that affect binding.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes that regulate IL-12A binding or downstream signaling. By selecting for cells with altered responses to IL-12, researchers can uncover novel components of the pathway. This unbiased approach is powerful for discovering new therapeutic targets.
Reporter Assays and Flow Cytometry
Reporter cell lines that express fluorescent or luminescent reporters under the control of IL-12-responsive promoters (e.g., STAT4-driven) can be used to measure pathway activity. Flow cytometry can assess surface binding of IL-12 to its receptor or detect intracellular IL-12A. These methods enable high-throughput screening of compounds or genetic perturbations.
How CRISPR Can Be Used to Study GO:0042164 interleukin-12 alpha subunit binding
Knockout
CRISPR knockout of IL12A or its binding partners can completely abolish the binding event, allowing researchers to study the consequences for cytokine assembly, secretion, and signaling. For example, IL12A knockout cell lines fail to produce functional IL-12 heterodimers, which can be rescued by reintroducing the gene. This approach is essential for validating the role of specific proteins in IL-12A binding.
Point Mutation
Introducing precise point mutations into IL12A or interacting domains via CRISPR base editing or homology-directed repair can reveal critical residues for binding. For instance, mutating cysteine residues involved in disulfide bond formation may disrupt subunit interaction. Such models help map the binding interface and understand disease-associated variants.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous IL12A locus enables tracking and purification of the alpha subunit under native conditions. This allows for proteomic identification of binding partners and real-time imaging of cytokine trafficking. Knock-in models are also useful for studying the dynamics of IL-12A interactions in vivo.
Overexpression
Overexpression of IL12A or its binding partners can amplify the binding signal and facilitate biochemical studies. However, overexpression may lead to non-physiological interactions, so results should be validated with endogenous models. Overexpression systems are particularly useful for producing recombinant proteins for structural studies.
How EDITGENE Supports interleukin-12 alpha subunit binding Research
Researchers studying interleukin-12 alpha subunit binding-related genes often need to determine whether a candidate gene is causally involved in cytokine assembly, receptor engagement, or immune signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of these pathways.
Contact EDITGENE today to design your custom CRISPR model for interleukin-12 alpha subunit binding research.
Frequently Asked Questions About interleukin-12 alpha subunit binding
What is interleukin-12 alpha subunit binding?
Interleukin-12 alpha subunit binding (GO:0042164) is a molecular function defined as the binding to the alpha subunit (p35/IL-12A) of the cytokine interleukin-12.
What genes are involved in interleukin-12 alpha subunit binding?
Key genes include IL12A (encoding the alpha subunit), IL12B (beta subunit), IL12RB1 and IL12RB2 (receptor subunits), and signaling molecules such as JAK2, TYK2, and STAT4.
What is the function of IL-12 alpha subunit?
The IL-12 alpha subunit (p35) combines with the beta subunit (p40) to form active IL-12, which drives Th1 immune responses and interferon-gamma production.
How is interleukin-12 alpha subunit binding studied?
Common methods include co-immunoprecipitation, surface plasmon resonance, CRISPR knockout screens, and reporter assays.
What diseases are associated with IL-12 alpha subunit binding?
Dysregulation of IL-12 signaling is linked to psoriasis, inflammatory bowel disease, and autoimmune conditions such as Sjögren's syndrome.
Can CRISPR be used to study interleukin-12 alpha subunit binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of the binding interface and functional consequences.
What are the synonyms for interleukin-12 alpha subunit binding?
Synonyms include CLMFp35 binding, IL-12A binding, IL-12p35 binding, and NKSFp35 binding.
Which cytokines share the IL-12 alpha subunit?
IL-12, IL-23, and IL-39 all contain the IL-12 alpha subunit (p35 or its homolog), making it a shared component of multiple inflammatory pathways.
What therapeutic antibodies target IL-12 alpha subunit binding?
Risankizumab targets IL-23 p19, and ustekinumab targets the shared p40 subunit; both indirectly affect IL-12 alpha subunit-containing cytokines.
How does interleukin-12 alpha subunit binding affect immune responses?
It is essential for IL-12 heterodimer assembly and receptor engagement, which activate JAK-STAT signaling and promote Th1 differentiation.
Conclusion
Interleukin-12 alpha subunit binding (GO:0042164) is a molecular function critical for the assembly, secretion, and signaling of IL-12 and related cytokines. Its involvement in inflammatory and autoimmune diseases makes it a compelling target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are accelerating our understanding of the proteins and mechanisms that regulate this binding event. Continued research will likely uncover new opportunities for modulating IL-12 family pathways in disease.
References
- 1. Gordon KB et al.. 2018. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.. Lancet 392(10148):650-661 PMID: 30097359
- 2. de Lima JD et al.. 2023. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.. Immunol Invest 52(3):364-397 PMID: 36745138
- 3. Dinarello CA. 1999. Interleukin-18.. Methods 19(1):121-32 PMID: 10525448
- 4. Takedatsu H et al.. 2008. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.. Gastroenterology 135(2):552-67 PMID: 18598698
- 5. Lu Z et al.. 2020. Interleukin 39: a new member of interleukin 12 family.. Cent Eur J Immunol 45(2):214-217 PMID: 33456334
- 6. Teos LY et al.. 2017. Genetics of Sjögren's syndrome.. Clin Immunol 182:41-47 PMID: 28476436
- 7. Vandenbroeck K et al.. 2004. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.. J Pharm Pharmacol 56(2):145-60 PMID: 15005873
- 8. Miyoshi J et al.. 2022. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis.. Expert Opin Drug Saf 21(1):1-8 PMID: 34511011
